Insulin Receptor
Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.
The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.
All Product Categories
-
Insulin Receptor Inhibitors
(62)
View all products
-
Insulin Receptor Agonists
(34)
View all products
-
Insulin Receptor Antagonists
(12)
View all products
-
Insulin Receptor Activators
(34)
View all products
-
Insulin Receptor Modulators
(5)
View all products
-
Insulin Receptor Inducer
(1)
View all products
-
Insulin Receptor Degrader
(1)
View all products
-
Insulin Receptor Substrates
(3)
View all products
-
Insulin Receptor Ligand
(1)
View all products
-
Insulin Receptor (INSR) Proteins
(5)
View all products
-
INSR/CD220 Proteins
(7)
View all products
-
Insulin Receptor Related Products (204)
Related Products (204)
-
Recombinant Proteins (8)
-
Antibodies (8)
-
Glymidine sodium
0 ImagesGlymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization.
-
GIPR antagonist 2
0 ImagesGIPR antagonist 2 is a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist with an IC50 of 7.2 nM in CHO-K1 cells. GIPR antagonist 2 can be used in research related to diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis.
-
Ceritinib-d7
0 ImagesSynonyms: LDK378 d7Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
-
GLP-1R/GIPR agonist-1
0 ImagesCat. No.: HY-P10302GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
-
Marmesinin
0 ImagesMarmesinin ((-)-Marmesinin; Ammijin) is an orally active furanocoumarin glycoside that enhances insulin secretion by inhibiting CYP1A2/CYP3A4 and Aldose Reductase, and modulating the PPARγ/PDX-1/IRS-2 pathway, while also exhibiting anti-inflammatory, antioxidant, and myocardial membrane-stabilizing effects. Marmesinin is used in research on type 2 diabetes, diabetic complications, myocardial injury, neurodegenerative diseases, and malaria.
-
(Pro3) GIP, human
0 ImagesCat. No.: HY-P3584CAS No.: 299898-52-5Synonyms: (Pro3) Gastric Inhibitory Peptide, human(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.
-
DA-JC4
0 ImagesDA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
-
Insulin receptor (1142-1153), pTyr1150
0 ImagesInsulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)
-
S961 TFA
0 ImagesCat. No.: HY-P2093AS961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
-
GIP (1-30)-Myr
0 ImagesCat. No.: HY-P2080CGIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10-9-10-6 M.
-
Herbimycin A
0 ImagesHerbimycin A is an antibiotic and protein tyrosine kinase inhibitor. Herbimycin A directly inhibits the autophosphorylation of p210 BCR-ABL with an IC50 of approximately 5 μM, and reduces Src kinase activity. Herbimycin A also induces the degradation of receptor tyrosine kinases such as insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (IR) and epidermal growth factor receptor (EGFR) via the ubiquitin-20S proteasome pathway. Herbimycin A directly modifies NF-κB p50, with the main target site involving Cys62, thereby blocking the DNA binding of p50 and NF-κB-driven gene expression. Herbimycin A can be used in studies related to tyrosine kinase signaling, chronic myeloid leukemia, NF-κB signaling, osteoclast function, apoptosis and cellular stress.
-
Insulin levels modulator
0 ImagesInsulin levels modulator (Example 49) is an orally active insulin secretagogue. Insulin levels modulator can be used for the research of type 2 diabetes and type 2 diabetes-related disorders.
-
Zenagamtide
0 ImagesCat. No.: HY-P11274CAS No.: 3005889-81-3Synonyms: Amycretin; NN 9487Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
-
CEP-14513
0 ImagesCat. No.: HY-111277CAS No.: 856693-04-4CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma.
-
NVP-AEW541 dihydrochloride
0 ImagesCat. No.: HY-50866BCAS No.: 2320261-63-8Synonyms: AEW541 dihydrochlorideNVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity.
-
TLK19781
0 ImagesCat. No.: HY-123547CAS No.: 309932-60-3TLK19781 is a non-peptide small molecule insulin receptor activator that increases the content of insulin-stimulated GLUT4 on the cell membrane and enhances the activity of insulin-stimulated glucose transport in cell and animal models of insulin resistance.
-
Acetyl Gastric Inhibitory Peptide (human)
0 ImagesCat. No.: HY-P3580CAS No.: 299898-33-2Synonyms: Human N-acetyl GIPAcetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
